Niti Aayog – Express Pharma

Working with Moderna to see make its COVID vaccine available in India: Govt

Delta Plus Variant is not yet classified as Variant of Concern: Dr VK Paul

Significant adverse effect unlikely with doses of different COVID-19 vaccines, but further scrutiny required: Govt

India will study claim of Sputnik Light: Dr VK Paul

8-10 months protection possible with COVID-19 vaccine: AIIMS director

Include pharma workforce in priority list for COVID-19 vaccination: Pharma associations

Vaccines in pipeline will work against the new COVID-19 variants: Dr K Raghavan

India ramping up API manufacturing: NITI Aayog CEO

Expert Committee discuss strategy for availability and delivery mechanism of COVID-19 vaccines

Expert Committee for COVID-19 vaccine administration to meet on August 12